Micromet/MedImmune’s Blinatumomab Shows Early Promise Of BiTE Antibodies
This article was originally published in The Pink Sheet Daily
Executive Summary
Immune-based cancer therapy demonstrated tumor regression and complete remission in non-Hodgkin’s lymphoma patients in an early study.